8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Apr 16, 2026·SEC
Material company update
Apr 8, 2026·SEC
MAIA Biotechnology, Inc.(MAIA)Earnings, Financials & Key Ratios
MAIA•AMEX
Price updated Jun 3, 2026
AboutMAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.Show more
- Revenue$0
- EBITDA-$24M-4.4%
- Net Income-$22M+3.7%
- EPS (Diluted)-0.70+33.3%
- ROE-745.24%+34.1%
MAIA Key Insights
MAIA Biotechnology, Inc. (MAIA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 27.5% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 44.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 19.3x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MAIA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MAIA Price & Volume
MAIA Biotechnology, Inc. (MAIA) stock price & volume — 10-year historical chart
Loading chart...
MAIA Growth Metrics
MAIA Biotechnology, Inc. (MAIA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.06%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.56%
Return on Capital
10 Years-781.18%
5 Years-315.81%
3 Years-403.17%
Last Year-476.18%
MAIA Recent Earnings
MAIA Biotechnology, Inc. (MAIA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 11, 2026EPS
$0.14
Est $0.18
+22.2%
Revenue
—
Q2 2026
May 8, 2026EPS
$0.14
Est $0.18
+22.2%
Revenue
—
Q2 2026
Mar 23, 2026EPS
$0.08
Est $0.13
+38.5%
Revenue
—
Q4 2025
Nov 7, 2025EPS
$0.27
Est $0.19
-42.1%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.14vs $0.18+22.2% | — |
| Q2 2026 | May 8, 2026 | $0.14vs $0.18+22.2% | — |
| Q2 2026 | Mar 23, 2026 | $0.08vs $0.13+38.5% | — |
| Q4 2025 | Nov 7, 2025 | $0.27vs $0.19-42.1% | — |
Based on last 12 quarters of dataView full earnings history →
MAIA Peer Comparison
MAIA Biotechnology, Inc. (MAIA) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TELO | 42.29M | 1.23 | -3.73 | -201.23% | ||||
 IMVT | 6.4B | 31.15 | -11.25 | -68.16% | 0.00 | |||
 AGEN | 134.09M | 3.22 | -947.06 | 10.37% | 52.16% | |||
 CYCN | 12.99M | 3.00 | -2.75 | 3.7% | -264.73% | -62.1% | ||
 TPVG | 218.42M | 5.38 | 4.41 | 36.55% | -3.39% | 1.33 | ||
 ACAD | 3.67B | 21.43 | 9.36 | 11.87% | 34.3% | 35.65% | 0.04 | |
 NKTR | 1.16B | 59.23 | -6.09 | -43.89% | -284.18% | -87% | 1.66 | |
 HALO | 8.28B | 69.82 | 27.27 | 37.55% | 23.13% | 126.27% | 43.89 |
Compare MAIA vs Peers
MAIA Biotechnology, Inc. (MAIA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MAIA Income Statement
MAIA Biotechnology, Inc. (MAIA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - | - |
Operating Expenses | 6.92M | 6.98M | 7.79M | 16.18M | 20.18M | 16.96M | 24.27M | 25.79M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 5.01M | 5.56M | 4.29M | 6.14M | 9.07M | 6.95M | 9.72B | 10.92M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 1.91M | 1.41M | 3.45M | 8.93M | 11.11M | 10.01M | 14.55B | 14.87M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 43.67K | 1.1M | 0 | 0 | -24.25B | 0 |
Operating Income | -6.92M▲ 0% | -6.98M▼ 0.8% | -7.79M▼ 11.6% | -16.18M▼ 107.7% | -20.18M▼ 24.8% | -16.96M▲ 16.0% | -24.27M▼ 43.1% | -25.79M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -0.78% | -11.63% | -107.74% | -24.77% | 15.98% | -43.12% | - |
EBITDA | 0 | 0 | -11.75M | -15.76M | -19.77M | -23.25M | -24.27M | -15.74M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | - | -34.14% | -25.4% | -17.65% | -4.37% | -31.66% |
D&A (Non-Cash Add-back) | 6.92M | 6.98M | 0 | 0 | 0 | 0 | 0 | 9.36M |
EBIT | -6.92M | -6.98M | -11.75M | -15.76M | -19.77M | -23.25M | -24.27M | -24.65M |
Net Interest Income | 242 | -31.55K | -825.53K | -5.1K | 27.63K | 318.31K | 313.95K | 343.53K |
Interest Income | 242 | - | 2.01K | 1.87K | 27.63K | 318.37K | 313.95K | 343.53K |
Interest Expense | - | 31.55K | 827.54K | 6.97K | 0 | 57 | 0 | 0 |
Other Income/Expense | 242 | 16.35K | -4.79M | 406.92K | 409.48K | -6.3M | 1.87M | 1.55M |
Pretax Income | -6.92M▲ 0% | -6.96M▼ 0.6% | -12.58M▼ 80.7% | -15.77M▼ 25.4% | -19.77M▼ 25.4% | -23.25M▼ 17.6% | -22.4M▲ 3.7% | -24.25M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -6.49M▲ 0% | -6.64M▼ 2.2% | -12.5M▼ 88.4% | -15.77M▼ 26.1% | -19.77M▼ 25.4% | -23.25M▼ 17.6% | -22.4M▲ 3.7% | -24.25M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -2.22% | -88.41% | -26.12% | -25.39% | -17.61% | 3.69% | -23.06% |
Net Income (Continuing) | -6.92M | -6.96M | -12.58M | -15.77M | -19.77M | -23.25M | -22.4M | -24.25M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 1.5M | 1.72M | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.61▲ 0% | -0.62▼ 1.6% | -1.18▼ 90.3% | -1.70▼ 44.1% | -1.49▲ 12.4% | -1.05▲ 29.5% | -0.70▲ 33.3% | -0.76▲ 0% |
EPS Growth % | - | -1.64% | -90.32% | -44.07% | 12.35% | 29.53% | 33.33% | 15.56% |
EPS (Basic) | -0.61 | -0.62 | -1.18 | -1.70 | -1.49 | -1.05 | -0.70 | - |
Diluted Shares Outstanding | 10.64M | 10.64M | 10.64M | 9.28M | 13.26M | 22.2M | 32.12M | 32.12M |
Basic Shares Outstanding | 10.64M | 10.64M | 10.64M | 9.28M | 13.26M | 22.2M | 32.12M | 32.12M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
MAIA Balance Sheet
MAIA Biotechnology, Inc. (MAIA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.73M | 746.5K | 10.67M | 11.81M | 7.56M | 10.15M | 9.7M | 35.32M |
Cash & Short-Term Investments | 1.71M | 663.46K | 10.57M | 10.95M | 7.15M | 9.6M | 8.66B | 34.41M |
Cash Only | 1.71M | 663.46K | 10.57M | 10.95M | 7.15M | 9.6M | 8.66B | 34.41M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 43.67K | 302.79K | 144.68K | 77.35K | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | -43.67K | 554.32K | 268.68K | 473.83K | -8.65B | 902.02K |
Total Non-Current Assets | 0 | 0 | 654.7K | 214K | 2.8K | 2.8K | 2.8K | 7.52K |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 654.7K | 214K | 2.8K | 2.8K | 2.8K | 7.52K |
Total Assets | 1.73M▲ 0% | 746.5K▼ 57.0% | 11.33M▲ 1417.4% | 12.02M▲ 6.1% | 7.57M▼ 37.1% | 10.16M▲ 34.2% | 9.7M▼ 4.4% | 35.32M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | -56.96% | 1417.36% | 6.13% | -37.06% | 34.21% | -4.44% | 95679.76% |
Total Current Liabilities | 374.56K | 1.69M | 2.15M | 3.27M | 4.94M | 3.83M | 5.84M | 6.32M |
Accounts Payable | 169.19K | 154.89K | 960.4K | 1.17M | 1.64M | 1.51M | 2.04M | 2.98M |
Days Payables Outstanding | - | - | - | - | - | - | - | - |
Short-Term Debt | 25K | 31.95K | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2.1K | 1.44M | 496.02K | 0 | 1.61M | 941.1K | 3.8M | 3.34M |
Current Ratio | 4.63x | 0.44x | 4.97x | 3.61x | 1.53x | 2.65x | 1.66x | 1.66x |
Quick Ratio | 4.63x | 0.44x | 4.97x | 3.61x | 1.53x | 2.65x | 1.66x | 1.66x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 35.17K | 669.06K | 0 | 245.34K | 2.15M | 2.69M | 1.49M | 1.24M |
Long-Term Debt | 9.17K | 431.8K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 26K | 237.26K | 0 | 245.34K | 2.15M | 2.69M | 1.49M | 1.24M |
Total Liabilities | 409.74K | 2.36M | 2.15M | 3.51M | 7.09M | 6.52M | 7.33M | 7.56M |
Total Debt | 34.17K | 463.75K | 0 | 0 | 0 | 0 | 0 | 0 |
Net Debt | -1.68M | -199.7K | -10.57M | -10.95M | -7.15M | -9.6M | -8.66B | -34.41M |
Debt / Equity | 0.03x | - | - | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 2.19x |
Interest Coverage | - | -221.12x | -14.20x | -2262.42x | - | -407975.42x | - | - |
Total Equity | 1.32M▲ 0% | -1.62M▼ 222.0% | 9.18M▲ 668.0% | 8.51M▼ 7.3% | 477.51K▼ 94.4% | 3.63M▲ 661.2% | 2.38M▼ 34.6% | 27.76M▲ 0% |
Equity Growth % | - | -222% | 668.04% | -7.33% | -94.39% | 661.16% | -34.63% | 65654.18% |
Book Value per Share | 0.12 | -0.15 | 0.86 | 0.92 | 0.04 | 0.16 | 0.07 | 0.86 |
Total Shareholders' Equity | -172.87K | -3.34M | 9.18M | 8.51M | 477.51K | 3.63M | 2.38M | 27.76M |
Common Stock | 442 | 443 | 758 | 1.1K | 1.7K | 2.62K | 3.86K | 6.07K |
Retained Earnings | -9.3M | -15.93M | -28.44M | -44.21M | -63.98M | -87.23M | -109.63M | -116M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -104.4K | 0 | 0 | -15.97K | -16.26K | -30.61K | -50.23K | -39.67K |
Minority Interest | 1.5M | 1.72M | 0 | 0 | 0 | 0 | 0 | 0 |
MAIA Cash Flow Statement
MAIA Biotechnology, Inc. (MAIA) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.57M | -1.84M | -4.12M | -12.1M | -13.07M | -15.7M | -18.84M | -18.84M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -17.83% | -123.56% | -193.39% | -8.06% | -20.15% | -20% | -93.22% |
Net Income | -6.49M | -6.96M | -12.58M | -15.77M | -19.77M | -23.25M | -22.4M | -24.25M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 0 | 3.89M | 2.72M | 2.32M | 3.09M | 1.91M | 2.63M | 2.26M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 4.66M | -28.02K | 4.61M | 1M | 526.53K | 6.88M | -579.4K | 685.31K |
Working Capital Changes | 269.46K | 1.25M | 1.13M | 352.78K | 3.09M | -1.24M | 1.5M | 1.35M |
Change in Receivables | 0 | 0 | 0 | -269.39K | 158.41K | 56.8K | 80.41K | 80.41K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 104.83K | -2.3K | 805.52K | 211.35K | 471.9K | -118.83K | 519.72K | 1.1M |
Cash from Investing | 187.56K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 187.56K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 2.22M | 798.05K | 14.03M | 12.48M | 9.27M | 18.18M | 17.91M | 43.5M |
Debt Issued (Net) | 10K | 668.87K | 7.43M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 2.09M | 50K | 5.74M | 13.97M | 11.42M | 18.75M | 18.52M | 43.91M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 125K | 79.19K | 860.43K | -1.5M | -2.15M | -578.1K | -617.13K | -412.46K |
Net Change in Cash | 1.71M▲ 0% | -1.05M▼ 161.2% | 9.91M▲ 1047.4% | 376.63K▼ 96.2% | -3.8M▼ 1109.0% | 2.45M▲ 164.5% | -943.27K▼ 138.5% | 23.55M▲ 0% |
Free Cash Flow | -1.57M▲ 0% | -1.84M▼ 17.8% | -4.12M▼ 123.6% | -12.1M▼ 193.4% | -13.07M▼ 8.1% | -15.7M▼ 20.1% | -18.84M▼ 20.0% | -19.95M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | -17.83% | -123.56% | -193.39% | -8.06% | -20.15% | -20% | -22.27% |
FCF per Share | -0.15 | -0.17 | -0.39 | -1.30 | -0.99 | -0.71 | -0.59 | -0.59 |
FCF Conversion (FCF/Net Income) | 0.24x | 0.28x | 0.33x | 0.77x | 0.66x | 0.68x | 0.84x | 0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MAIA Key Ratios
MAIA Biotechnology, Inc. (MAIA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -330.58% | -178.29% | -440.12% | -1131.02% | -745.24% | -4.03% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | 1.23% |
| Debt / Equity | - | - | - | - | - | - | 0.00x |
| Interest Coverage | -221.12x | -14.20x | -2262.42x | - | -407975.42x | - | - |
| FCF Conversion | 0.28x | 0.33x | 0.77x | 0.66x | 0.68x | 0.84x | 0.82x |
Related:MAIA Dividend History·MAIA Revenue History·MAIA Price History·MAIA P/E History·MAIA Financial Ratios·MAIA Institutional Holders
MAIA SEC Filings & Documents
MAIA Biotechnology, Inc. (MAIA) SEC filings — annual & quarterly reports (10-K, 10-Q)
MAIA Frequently Asked Questions
MAIA Biotechnology, Inc. (MAIA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MAIA Biotechnology, Inc. (MAIA) grew revenue by 0.0% over the past year. Growth has been modest.
MAIA Biotechnology, Inc. (MAIA) reported a net loss of $24.2M for fiscal year 2025.
Dividend & Returns
MAIA Biotechnology, Inc. (MAIA) has a return on equity (ROE) of -745.2%. Negative ROE indicates the company is unprofitable.
MAIA Biotechnology, Inc. (MAIA) had negative free cash flow of $20.0M in fiscal year 2025, likely due to heavy capital investments.